Health
Triggering tumor antiviral immune response in triple negative breast cancer – EurekAlert
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast…
HOUSTON – (Jan. 14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection. Researchers suggest this mechanism could open new avenues…
-
Business24 hours agoDicker Data rides the AI trend to double digit growth
-
Noosa News24 hours agoBob Katter threatens Channel 9 journalist for asking question on family heritage
-
Business21 hours agoDoes Macquarie rate Rio Tinto shares a buy, hold or sell after its big news?
-
Noosa News23 hours ago‘Large scale’ cattle duffing in the NT under investigation